# Study of SHR6390 in Renal Insufficiency and Healthy Subjects

> **NCT05515289** · PHASE1 · UNKNOWN · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 30 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** SHR6390

## Key facts

- **NCT ID:** NCT05515289
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-12-18
- **Primary completion:** 2023-08-28
- **Final completion:** 2023-09-28
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2023-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05515289

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05515289, "Study of SHR6390 in Renal Insufficiency and Healthy Subjects". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05515289. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*